The MarketWatch News Department was not involved in the creation of this content. --Findings support the versatility of Capricor's exosome technology, enabling efficient and scalable loading of siRNAs ...
Multidrug-resistant bacteria pose a major threat to human health. Manipulation of bacterial genes at the transcriptional level is a potential strategy to fight antibiotic-resistant bacterial ...
--Findings support the versatility of Capricor’s exosome technology, enabling efficient and scalable loading of siRNAs and PMOs to support future clinical development-- The poster titled, “A ...
--Findings support the versatility of Capricor’s exosome technology, enabling efficient and scalable loading of siRNAs and PMOs to support future clinical development-- SAN DIEGO, Nov. 24, 2025 (GLOBE ...
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc., (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback